Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures
Public ClinicalTrials.gov record NCT01142193. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures
Study identification
- NCT ID
- NCT01142193
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Upsher-Smith Laboratories
- Industry
- Enrollment
- 249 participants
Conditions and interventions
Conditions
Interventions
- USL255 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2010
- Primary completion
- Nov 30, 2012
- Completion
- Dec 31, 2012
- Last update posted
- May 21, 2014
2010 – 2013
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Ventura | California | — | — |
| Not listed | Gainesville | Florida | — | — |
| Not listed | Gulf Breeze | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Pensacola | Florida | — | — |
| Not listed | Port Charlotte | Florida | — | — |
| Not listed | Boise | Idaho | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Waldorf | Maryland | — | — |
| Not listed | Chesterfield | Missouri | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | New Brunswick | New Jersey | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Toledo | Ohio | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Temple | Texas | — | — |
| Not listed | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01142193, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 21, 2014 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01142193 live on ClinicalTrials.gov.